Chromatographic and immunochemical approaches to the analysis of the HIV protease inhibitor saquinavir in plasma

被引:15
|
作者
Wiltshire, HR
Wiltshire, BG
Clarke, AF
Worth, E
Prior, KJ
Tjia, JF
机构
[1] Roche Discovery Welwyn, Welwyn Garden City AL7 3AY, Herts, England
[2] Univ Liverpool, Dept Pharmacol & Therapeut, Liverpool L69 3GE, Merseyside, England
关键词
bioanalysis; HPLC/UV; radioimmunoassay; HIV protease inhibitor; saquinavir;
D O I
10.1006/abio.2000.4545
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
The development of the HIV protease inhibitor saquinavir (Ro 31-8959) required a range of analytical methods for its measurement in biological fluids. This paper describes the development of isocratic, reverse-phase HPLC/UV methods for the routine measurement of plasma levels of the drug together with a more sensitive radioimmunoassay, The performance of the two assays is compared with that of an HPLC/MS/MS method previously published and has been shown to be satisfactory, with coefficients of variation of calibration standards and quality control samples within the usual outside limits of +/-15%. The HPLC/UV method can be routinely applied for concentrations down to 10-20 ng/ml and a lower limit of quantification of 1 ng/ml from 1 mi of human plasma is possible. The radioimmunoassay was developed for the specific measurement of saquinavir concentrations in human, HIV-positive plasma samples and has a lower limit of quantification of 0.5-1.0 ng/ml, Some preliminary findings suggested that it might not be specific in rat plasma and no attempts have been made to quantify any nonclinical samples with this technique. If still greater sensitivity is required, recourse can be made to the HPLC/MS/MS assay. (C) 2000 Academic Press.
引用
收藏
页码:105 / 114
页数:10
相关论文
共 50 条
  • [1] The HIV-1 protease inhibitor saquinavir is a radiosensitizer
    Himmelsbach, J
    McBride, WH
    Pajonk, F
    STRAHLENTHERAPIE UND ONKOLOGIE, 2002, 178 : 37 - 37
  • [2] Saquinavir, an HIV protease inhibitor, is transported by P-glycoprotein
    Kim, AE
    Dintaman, JM
    Waddell, DS
    Silverman, JA
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 1998, 286 (03): : 1439 - 1445
  • [3] IMMUNOCHEMICAL ANALYSIS OF THE ERYTHRINA PROTEASE INHIBITOR
    HEUSSENSCHEMMER, C
    BARRON, J
    VEENSTRA, H
    DOWDLE, EB
    SOUTH AFRICAN JOURNAL OF SCIENCE, 1993, 89 (03) : 136 - 140
  • [4] Metabolic effects of the HIV protease inhibitor — saquinavir in differentiating human preadipocytes
    Monika Bociąga-Jasik
    Anna Polus
    Joanna Góralska
    Urszula Czech
    Anna Gruca
    Agnieszka Śliwa
    Aleksander Garlicki
    Tomasz Mach
    Aldona Dembińska-Kieć
    Pharmacological Reports, 2013, 65 : 937 - 950
  • [5] Evaluation of factors to decrease plasma concentration of an HIV protease inhibitor, saquinavir in ethanol-treated rats
    Shibata, N
    Kageyama, M
    Kimura, K
    Tadano, J
    Hukushima, H
    Namiki, H
    Yoshikawa, Y
    Takada, K
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2004, 27 (02) : 203 - 209
  • [6] Grapefruit juice enhances the bioavailability of the HIV protease inhibitor saquinavir in man
    Kupferschmidt, HHT
    Fattinger, KE
    Ha, HR
    Follath, F
    Krähenbühl, S
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1998, 45 (04) : 355 - 359
  • [7] Metabolic effects of the HIV protease inhibitor - saquinavir in differentiating human preadipocytes
    Bociaga-Jasik, Monika
    Polus, Anna
    Goralska, Joanna
    Czech, Urszula
    Gruca, Anna
    Sliwa, Agnieszka
    Garlicki, Aleksander
    Mach, Tomasz
    Dembinska-Kiec, Aldona
    PHARMACOLOGICAL REPORTS, 2013, 65 (04) : 937 - 950
  • [9] Relationship Between Plasma Protease Inhibitor Concentrations and Lipid Elevations in HIV Patients on a Double-Boosted Protease Inhibitor Regimen (Saquinavir/Lopinavir/Ritonavir)
    Rhee, Martin S.
    Hellinger, James A.
    Sheble-Hall, Sandy
    Cohen, Calvin J.
    Greenblatt, David J.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 50 (04): : 392 - 400
  • [10] Saquinavir, the pioneer antiretroviral protease inhibitor
    la Porte, Charles J. L.
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2009, 5 (10) : 1313 - 1322